A. Seddighzadeh

发表

S. Goldhaber, G. Piazza, A. Seddighzadeh, 2008, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Double trouble for 2,609 hospitalized medical patients who developed deep vein thrombosis: prophylaxis omitted more often and pulmonary embolism more frequent.

S. Goldhaber, G. Piazza, A. Seddighzadeh, 2007, Chest.

Population‐Based Pharmacokinetic and Exposure‐Efficacy Analyses of Peginterferon Beta‐1a in Patients With Relapsing Multiple Sclerosis

I. Nestorov, Yue Cui, A. Deykin, 2017, Journal of clinical pharmacology.

Deep vein thrombosis in patients with chronic kidney disease

S. Goldhaber, G. Piazza, A. Seddighzadeh, 2008, Thrombosis and Haemostasis.

Gastrointestinal Complications After 3 Months of Dual Antiplatelet Therapy for Drug-eluting Stents as Assessed by Wireless Capsule Endoscopy

S. Goldhaber, S. Parasuraman, A. Seddighzadeh, 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Heart failure in patients with deep vein thrombosis.

S. Goldhaber, G. Piazza, A. Seddighzadeh, 2008, The American journal of cardiology.

Once-daily fondaparinux monotherapy without warfarin for long-term treatment of venous thromboembolism.

S. Goldhaber, M. Gerhard-Herman, S. Parasuraman, 2007, Thrombosis and haemostasis.

Venous thromboembolism in patients with active cancer

S. Goldhaber, A. Seddighzadeh, Ranjitha S. Shetty, 2007, Thrombosis and Haemostasis.

Chronic obstructive pulmonary disease and deep vein thrombosis: a prevalent combination

S. Goldhaber, G. Piazza, A. Seddighzadeh, 2008, Journal of Thrombosis and Thrombolysis.

Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children.

D. Magen, Y. Frishberg, T. Mcgregor, 2021, Genetics in medicine : official journal of the American College of Medical Genetics.

Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function

I. Nestorov, T. Marbury, A. Seddighzadeh, 2014, Journal of clinical pharmacology.

COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects

I. Nestorov, K. Dawson, B. Werneburg, 2016, British journal of clinical pharmacology.

Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial

R. Bermel, B. Kieseier, S. Newsome, 2016, Therapeutic advances in neurological disorders.

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

D. Arnold, P. Calabresi, L. Balcer, 2014, The Lancet Neurology.

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE

D. Arnold, P. Calabresi, S. Sheikh, 2015, Multiple sclerosis.

Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study

P. Calabresi, K. Selmaj, Yue Cui, 2014, Expert opinion on drug delivery.

Venous thromboembolism in patients undergoing surgery: Low rates of prophylaxis and high rates of filter insertion

S. Goldhaber, U. Zurawska, A. Seddighzadeh, 2007, Thrombosis and Haemostasis.

PEGylated Interferon Beta-1a Pharmacokinetics, Pharmacodynamics, and Safety in Subjects with Normal or Impaired Renal Function (P06.165)

A. Seddighzadeh, Xiao Hu, Larisa Miller, 2012 .

Deep Vein Thrombosis in Orthopedic Surgery

S. Goldhaber, G. Piazza, M. Calfon, 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Strains of Ehrlichia chaffeensis in Southern Indiana, Kentucky, Mississippi, and North Carolina

C. Fuqua, K. Clay, A. Seddighzadeh, 2009, Journal of medical entomology.

Clinical Efficacy and Safety of Peginterferon beta-1a in Relapsing Multiple Sclerosis: Data from the Pivotal Phase 3 ADVANCE Study (S31.006)

D. Arnold, P. Calabresi, L. Balcer, 2013 .

Interim Analysis of 2-year Clinical Efficacy and Safety of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis: Data from the Pivotal Phase 3 ADVANCE Study (S4.005)

D. Arnold, S. Sheikh, B. Kieseier, 2014 .

Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

D. Arnold, P. Calabresi, L. Balcer, 2014, The Lancet Neurology.

Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial

R. Bermel, B. Kieseier, S. Newsome, 2016, Therapeutic advances in neurological disorders.